Latest 2-Oxazolidone Stories
Treatment with a newer antibiotic, tedizolid phosphate, once daily for 6 days was statistically noninferior (no worse than) in efficacy to the antibiotic linezolid twice daily for 10 days for both early (at day 2 to 3) and sustained (at day 11) clinical responses in patients with acute bacterial skin and skin structure infections.
SAN DIEGO, Oct. 4 /PRNewswire/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will participate in a panel discussion on antibiotic drug development at Citi's 5th Annual Biotech Day.
SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development.
WALTHAM, Mass., June 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of two emerging agents from Forest/AstraZeneca/Takeda and Trius will drive the methicillin-resistant Staphylococcus aureus (MRSA) drug market to increase from $631 million in 2009 to $752 million in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor 2010 findings...
SAN DIEGO, June 16 /PRNewswire/ -- Trius Therapeutics, Inc.
SAN DIEGO, March 29 /PRNewswire/ -- Trius Therapeutics, Inc.